BMRA
What one share of Biomerica holds
In Vitro and In Vivo Diagnostic Substances
Biomerica’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-08-31; the balance sheet is as of 2026-08-31.
| Sales | $1.41 |
|---|---|
| Profit | −$1.63 |
| Cash and investments | $0.59 |
| Book value | $0.79 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | $6.84 | $0.64 | $0.19 | −$0.02 | — | $5.73 |
| 2013 | $6.95 | $0.58 | $0.28 | $1.22 | — | $6.42 |
| 2014 | $5.56 | −$0.23 | $0.15 | −$1.08 | — | $6.27 |
| 2015 | $5.26 | −$0.32 | $0.01 | −$0.44 | — | $5.92 |
| 2016 | $5.39 | −$1.57 | $0.10 | −$0.32 | — | $5.11 |
| 2017 | $5.56 | −$0.87 | $0.09 | −$0.79 | — | $4.22 |
| 2018 | $5.19 | −$1.37 | $0.12 | −$1.22 | — | $3.89 |
| 2019 | $4.52 | −$2.08 | $0.09 | −$2.04 | — | $3.29 |
| 2020 | $5.27 | −$2.11 | $0.03 | −$3.41 | — | $9.69 |
| 2021 | $4.83 | −$4.99 | $0.09 | −$3.61 | — | $6.00 |
| 2022 | $11.91 | −$2.86 | $0.04 | −$0.34 | — | $5.18 |
| 2023 | $3.02 | −$4.04 | $0.04 | −$3.13 | — | $5.58 |
| 2024 | $2.57 | −$2.84 | $0.02 | −$2.57 | — | $3.13 |
| 2025 | $2.31 | −$2.16 | — | −$1.67 | — | $1.61 |
| 2026 | $1.53 | −$1.30 | — | −$1.17 | — | $0.82 |